ZYME has 36-month beta value of 1.12. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 1 as “sell.”
The public float for ZYME is 67.85M, and currently, short sellers hold a 6.14% ratio of that float. The average trading volume of ZYME on November 05, 2024 was 668.65K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ZYME) stock’s latest price update
The stock price of Zymeworks BC Inc (NASDAQ: ZYME) has surged by 11.14 when compared to previous closing price of 13.28, but the company has seen a 11.48% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-04 that The PDUFA date for potential approval of Zanidatamab for the treatment of patients with 2nd-line biliary tract cancer set for November 29th of 2024. Progression-free survival data from the phase 3 HERIZON-GEA-01 study using Zanidatamab + chemotherapy plus or minus tislelizumab for treatment of patients with 1st-line GEA is expected in Q2 of 2025. Zanidatamab is being developed in collaboration with two big pharmaceutical companies, which are Jazz Pharmaceuticals and BeiGene.
ZYME’s Market Performance
ZYME’s stock has risen by 11.48% in the past week, with a monthly rise of 17.42% and a quarterly rise of 45.42%. The volatility ratio for the week is 6.54% while the volatility levels for the last 30 days are 3.78% for Zymeworks BC Inc The simple moving average for the past 20 days is 10.65% for ZYME’s stock, with a 38.93% simple moving average for the past 200 days.
Analysts’ Opinion of ZYME
Many brokerage firms have already submitted their reports for ZYME stocks, with Wells Fargo repeating the rating for ZYME by listing it as a “Equal Weight.” The predicted price for ZYME in the upcoming period, according to Wells Fargo is $12 based on the research report published on November 01, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see ZYME reach a price target of $12. The rating they have provided for ZYME stocks is “Overweight” according to the report published on March 21st, 2023.
H.C. Wainwright gave a rating of “Neutral” to ZYME, setting the target price at $8 in the report published on January 04th of the previous year.
ZYME Trading at 16.70% from the 50-Day Moving Average
After a stumble in the market that brought ZYME to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 5.05% of gains for the given period.
Volatility was left at 3.78%, however, over the last 30 days, the volatility rate increased by 6.54%, as shares surge +18.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +29.59% upper at present.
During the last 5 trading sessions, ZYME rose by +11.48%, which changed the moving average for the period of 200-days by +49.39% in comparison to the 20-day moving average, which settled at $13.34. In addition, Zymeworks BC Inc saw 42.06% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZYME starting from Galbraith Kenneth, who sale 18,198 shares at the price of $10.65 back on Jan 05 ’24. After this action, Galbraith Kenneth now owns 29,468 shares of Zymeworks BC Inc, valued at $193,849 using the latest closing price.
Galbraith Kenneth, the Chair & CEO of Zymeworks BC Inc, sale 5,706 shares at $11.22 during a trade that took place back on Jan 08 ’24, which means that Galbraith Kenneth is holding 23,762 shares at $63,996 based on the most recent closing price.
Stock Fundamentals for ZYME
Current profitability levels for the company are sitting at:
- -551.32 for the present operating margin
- -0.02 for the gross margin
The net margin for Zymeworks BC Inc stands at -481.26. The total capital return value is set at -0.09. Equity return is now at value -28.73, with -21.79 for asset returns.
Based on Zymeworks BC Inc (ZYME), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -3.39. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -4750.88.
Currently, EBITDA for the company is -119.52 million with net debt to EBITDA at 2.98. When we switch over and look at the enterprise to sales, we see a ratio of -1625.79. The receivables turnover for the company is 0.0for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.10.
Conclusion
To put it simply, Zymeworks BC Inc (ZYME) has had a better performance in recent times. Analysts have a bearish opinion on the stock, with some rating it as a “sell” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
